Leo Pharma UK picked up three awards at last night's PMEAs (Pharmaceutical Market Excellence Awards), including the prize for small company of the year.
Leo's Princes Risborough-based affiliate beat Celgene and Astellas to take home the award for best company with a turnover under £150m, thanks to the way it transformed its approach to marketing and business.
"The transformation from traditional corporation to foundation has led to Leo reinvesting profits into development and impressive new talent being attracted to the organisation,” the PMEA judges said.
They added: “There is a sense of significant achievement within the company, and it's great to see the UK entity taking a lead within the entire organisation, with their truly multifunctional methodology being adopted throughout LEO Pharma."
There were further triumphs for Leo at the 2012 PMEAs, with a win (in association with Langland) in the Saatchi & Saatchi Health Award for Launch Excellence.
The company's UK launch of Dovobet Gel (calcipotriol/betamethasone dipropionate) for psoriasis in January 2011 was the largest in the history of dermatology.
The judges felt the company produced “a really comprehensive campaign that clearly showed they had done their homework”, recognising the issues that patients and their GPs faced in understanding the condition and its treatment.
Leo also picked up the Excellence in Provision of Patient Services, this time in association with Atlantis Healthcare, for its 'touch' Patient Support Programme.
In conjunction with health psychologists, dermatologists and patients, Leo developed 'touch' – an evidence-based support programme designed to improve adherence and health outcomes for people living with psoriasis.
Available to everyone with psoriasis aged over 18 in the UK (and their loved ones), users can access the 'touch' website and helpline, and also receive belief-based interventional content through a variety of media channels.